Shares of Canadian biotechnology company Zymeworks Inc. (ZYME) are trading down 7 percent on Tuesday morning.
The other day, the company announced that Chief Medical Officer Diana Hausman will be transitioning out from her post and will assume an executive advisory role until November 15. The company had also announced that Senior Vice President of Clinical Research Neil Josephson will take over as interim CMO.
The share was trading at $25.78, down $1.71 on the NYSE.
The company's stock has traded between $25.26 and $59.03 during the last 52-week period.
For comments and feedback contact: editorial@rttnews.com
Get Access to Premium Stock Alerts with RTT Intelligent Investor.
